Extracorporeal Photopheresis for Medicare Recipients of Lung Allografts

Conditions:Bronchitis, Pulmonary
Therapuetic Areas:Pulmonary / Respiratory Diseases
Age Range:18 - Any
Start Date:January 2015
End Date:December 2023
Contact:Mary Clare Derfler, RN, MSN

Use our guide to learn which trials are right for you!

Extracorporeal Photopheresis for the Management of Progressive Bronchiolitis Obliterans Syndrome in Medicare-Eligible Recipients of Lung Allografts

The primary aims of this study is to determine the efficacy and tolerability of
Extracorporeal Photopheresis (ECP) for the treatment of either refractory (240) or newly
diagnosed (739) Bronchiolitis Obliterans Syndrome (BOS) in patients after lung
transplantation.In compliance with the Centers for Medicare and Medicaid Services' (CMS)
Coverage with Evidence Development (CED) decision, the study will collect specified
demographic, comorbidity, treatment, and outcome data exclusively for Medicare beneficiaries
who are treated with Extracorporeal Photopheresis for either refractory or New Bronchiolitis
Obliterans Syndrome .

Lung transplantation has become the treatment of choice for selected patients with end-stage
lung disease. Long-term survival after transplantation remains disappointing. Chronic
rejection bronchiolitis obliterans syndrome has emerged as the leading obstacle to better
long-term outcomes, and is the leading cause of death beyond the first year after
transplantation. This disorder is a fibroproliferative scarring process that involves the
narrowing of the airway lumen and ultimately complete luminal obliteration. Physiologically
and clinically, this luminal narrowing results in airflow limitation and breathlessness.
Histologic confirmation of Bronchiolitis Obliterans Syndrome is difficult with bronchoscopy
obtained lung biopsies because of the patchy distribution of the disorder and inadequate
sampling of small airways with transbronchial lung biopsies. As a result Bronchiolitis
Obliterans Syndrome is diagnosed and staged by the decline in Forced Expiratory Volume
measurement from a pulmonary function test.

In general, bronchiolitis obliterans syndrome is treated by intensifying the
immunosuppressive regimen. The specific approach is variable from center to center, but
typically includes optimizing the maintenance immunosuppressive regimen to include tacrolimus
and mycophenolate mofetil, high-dose steroids, and a course of anti-thymocyte globulin.
Despite treatment, most patients continue to show progressive decline in lung function
resulting in worsening functional status, quality of life, and ultimately graft failure and

Extracorporeal photopheresis has been used at some centers as a salvage treatment for
progressive bronchiolitis obliterans syndrome. Extracorporeal photopheresis involves
separating the patient's blood into a leukocyte-enriched component (buffy coat) and a
leukocyte-depleted component. The buffy coat is then photosensitized with 8-methoxypsoralen
and treated with ultraviolet light within a photosensitization chamber, resulting in
leukocyte apoptosis. Although the exact mechanism of action of extracorporeal photopheresisis
unclear, re-infusion of this apoptotic leukocyte population into the patient's circulation is
thought to result in alterations in antigen presenting cells, cytokine profiles, and the
expansion of regulatory T cells.

On May 2, 2012, Centers for Medicare & Medicaid Services issued a Decision Memo stating that
Extracorporeal photopheresis is covered for Medicare beneficiaries for the treatment of
bronchiolitis obliterans syndrome following lung allograft transplantation only when the
procedure is provided under a clinical research study.

This study looks at (1) Early detection of bronchiolitis obliterans or refractory
bronchiolitis obliterans syndrome using a standardized, more frequent spirometry monitoring
approach (i.e., defined as using either more frequent laboratory based spirometry every 4-8
weeks) and (2) Early implementation of Extracorporeal photopheresis in both participants with
early stage refractory bronchiolitis obliterans syndrome and also as first line therapy in a
subset of participants at the initial diagnosis of bronchiolitis obliterans syndrome, in the
context of a new randomized controlled trial.

The study will look at whether certain coexisting disease states or patient-related
demographic, functional, treatment-related or diagnostic variables (e.g. extent or
statistical significance of the rate of pre-Extracorporeal Photopheresis - Forced Expiratory
Volume decline) might prove to have predictive value in identifying subsets of bronchiolitis
obliterans syndrome patients that are likely, or unlikely, to experience reduced rate of
decline or stabilization in Forced Expiratory Volume following extracorporeal photopheresis
treatment. Therefore this study will look to enroll a large series of patients from multiple
United States centers to confirm that Extracorporeal Photopheresis significantly reduces the
rate of Forced Expiratory Volume decline in bronchiolitis obliterans syndrome patients
refractory to standard immunosuppressive drug therapy, and to capture and assess specified
patient demographic, treatment-related, diagnostic, functional and co-morbidity-related
variables that may predict outcomes after Extracorporeal Photopheresis therapy.

This study includes a randomized controlled trial that will compare outcomes in patients with
an initial diagnosis of bronchiolitis obliterans syndrome or New bronchiolitis obliterans
syndrome who receive either conventional (i.e., that involves the standard of care at the
respective enrolling center) or Extracorporeal Photopheresis for first line management of New
bronchiolitis obliterans syndrome. The randomized controlled trial component of the study
will enable evaluation of potential survival and quality of life benefits of early treatment
of bronchiolitis obliterans syndrome with first-line Extracorporeal Photopheresis .

Subjects with Refractory bronchiolitis obliterans syndrome who agree to participate in the
study will be informed of the following: to limit the use (and attendant risks) of
Extracorporeal Photopheresis therapy to those patients who are most likely to benefit, their
eligibility to receive Extracorporeal Photophereis within the study will be determined by the
study team's analysis of their pre-enrollment pulmonary function testing along with input
from their physician.

Subjects with Newly-Diagnosed Bronchiolitis Obliterans syndrome who agree to participate in
the study will be informed that they will be randomly assigned to either a control group
(Control) who will receive the local Standard of Care for management of their Bronchiolitis
Obliterans Syndrome or to an Early Photopheresis Intervention group who will receive
Extracorporeal Photopheresis as first line management of Bronchiolitis Obliterans Syndrome.

The protocol states specific inclusion and exclusion criteria for both the Refractory
Bronchiolitis Obliterans syndrome participant and the newly diagnosed Bronchiolitis
Obliterans syndrome participant. Once eligibility is confirmed and the patient has provided
informed consent, all Forced Expiratory Volume measurements captured within the 12 months
prior to enrollment will be entered in the electronic database. Based on the slope of the
Forced Expiratory Volume and achievement of a statistically significant rate of decline in
lung function in the Forced Expiratory Volume the Refractory Bronchiolitis Obliterans
syndrome participant will be electronically assigned to either Extracorporeal Photopheresis
treatment or Observation. The newly diagnosed Bronchiolitis Obliterans syndrome participant
will be randomized to either Extracorporeal Photopheresis treatment and standard
immunosuppression therapy or Control which is Standard immunosuppression Therapy.

The participant will be assigned a unique identification number created from the electronic
data base. The patient demographics, co-morbidities, medical history including date of lung
transplantation, underlying disease necessitating lung transplantation, vital signs, height,
weight, and current immunosuppression regimen will be entered at baseline. A Quality of Life
Questionnaire will be asked at baseline and every 3 months the first year and then annually.
A pulmonary function test will be captured every 30 days on all patients except the
Refractory Bronchiolitis Obliterans syndrome participant assigned to Observation. Pulmonary
function tests will be ordered on the Observation patient at the physician's discretion.
Certain de-identified source documents will be required and verified on all forms
electronically submitted. Data points will be verified against de-identified source by the
Data Coordinating Center. The online data entry portal and study database will contain a
mechanism to a) clearly denote the status of each submitted Case Report Form, including
whether the case report form is complete; b) list the source documentation needed c) indicate
if the site staff member and investigator have attested to the validity of the data on the
Case Report Form; and d) indicate if the Data Coordinating Center has verified the accuracy
of key elements of the study data and what data queries remain. This centralized monitoring
will complement our on-site monitoring visits. For most sites an initial on site monitoring
visit will be soon after the first three patients are enrolled to ensure that the site
personnel understand study processes and expectations, and to permit early completion of
additional training to address any deficiencies. Should remote or on-site monitoring reveal
areas of particular deficiency or concern, the monitoring plan will be adjusted to focus on
those particular areas for the site. In general, sites and patients affiliated with a major
violation will be monitored with greater completeness. Sites deemed to be largely compliant
with the protocol and regulatory requirements based upon the initial monitoring visit are
expected to have subsequent visits performed at a reduced level of frequency. Overall, the
study team will seek to optimize resource use by focusing on the most critical data elements
that may impact subject safety and/or data quality and integrity.

Participants who receive Extracorporeal Photopheresis treatment will receive 24
Extracorporeal Photopheresis treatments over the 6-month period following enrollment.

Allowed Treatment for Refractory Bronchiolitis Obliterans syndrome patients in the
Observation will be ordered at the physicians discretion.

Treatment for the Newly Diagnosed Bronchiolitis Obliterans syndrome patients in the Control
Arm of the randomized control trial will be dictated by the standard of care within each
enrolling institution and will involve changes in immunosuppressive agents. These patients
will not be eligible to receive Extracorporeal Photopheresis treatment.

Other than Extracorporeal Photopheresis, no other interventions for Bronchiolitis Obliterans
syndrome will be used except for Azithromycin for patients in the randomized Early
Photopheresis Intervention.

An improvement in the Forced Expiratory Volume measurement taken from the pulmonary function
test will be used to assess the success or the benefit of the Extracorporeal Photopheresis
treatment. Patient's will have spirometry the first week of therapy, and repeated every 30
days for the first year, and then annually. All patients will be followed for 5 years.There
are considerations for crossover built into the protocol.

Statistical Methods.A clinical response will be determined using Forced Expiratory Volume as
primary endpoint and will be defined as a 50% or greater reduction in the rate of decline of
Forced Expiratory Volume assessed by comparing the average rate of Forced Expiratory Volume
decline over the 6 months prior to Extracorporeal Photopheresis against the average rate of
Forced Expiratory Volume decline over the 12 months following initiation of Extracorporeal

Survival Primary Outcome: Mortality three years after diagnosis of Bronchiolitis Obliterans
syndrome using standard of care management of Bronchiolitis Obliterans syndrome is 52%.
Assuming 15% exclusion related to early crossover and a 5% loss to follow-up of enrolled
patients, 739 patients who meet the standardized criteria for Bronchiolitis Obliterans
syndrome would need to be enrolled and randomly assigned to either the Early Photopheresis
Intervention or control cohorts to detect a difference. The outcomes between the two
Bronchiolitis Obliterans syndrome disease severity strata will be assessed separately. The
patient will be followed for up to five years or until their date of death and the following
data will be collected annually after the first year: Spirometry results, the number of
maintenance Extracorporeal Photopheresis treatments performed and Quality Of Life surveys
will be tabulated.


1. Age (18 years old or older).

2. Medicare-eligible (i.e., patients with both Part A and Part B) status

3. Lung transplant recipient (combined organ transplant recipients, e.g. heart-lung or
liver-lung recipients, are eligible).

4. Patients with a diagnosis of BOS using at least two laboratory based FEV1 values
obtained at least three weeks apart that are both at least 20% lower than baseline
FEV1 using the International Society for Heart and Lung Transplantation (ISHLT)
definition (The average of the two highest FEV1 measurements obtained at least 3 weeks
apart after transplantation).

5. Refractory BOS defined as ongoing decline in FEV1 despite at least one of the
following treatments: azithromycin, high-dose steroid, anti-thymocyte globulin, total
lymphoid irradiation, sirolimus, or everolimus.

6. At minimum five recorded FEV1 measurements obtained at intervals of at least two weeks
apart, over the 6 months preceding study enrollment, of which one FEV1 must be within
two weeks prior to enrollment.

7. History of frequent spirometry monitoring defined as having had regular FEV1
measurements during the preceding four months prior to enrollment with no time
interval between FEV1 measurements that exceeds 8 weeks.

8. A documented clinical assessment including a physical assessment and Complete Blood
Count (CBC) with White Blood Cell Count (WBC) within two weeks prior to enrollment.

INCLUSION criteria for NEWLY Diagnosed BOS

1. Age (18 years old or older)

2. Medicare-eligible status (i.e., patients with both Part A and Part B)

3. Lung transplant recipient (combined organ transplant recipients, e.g. heart-lung or
liver-lung recipients, are eligible).

4. History of close FEV1 monitoring prior to diagnosis of new BOS defined as having had
either of the two monitoring approaches:

Frequent laboratory based spirometry defined as having had regular FEV1 measurements
during the preceding six months prior to diagnosis of new BOS with no time interval
between FEV1 measurements that exceeds 8 weeks.

Frequent Home Spirometry through a Standardized Home Spirometry Method: this Method is
currently being finalized and will not be utilized to meet this close monitoring
enrollment criteria until it is InIRB approved.

5. Diagnosis of new BOS (i.e., "new BOS" is defined as within six weeks of enrollment)
based on laboratory-based spirometric FEV1 measurements obtained on at least two
separate occasions (i.e., at least 3 weeks apart) that have declined by more than 20%
from post-transplant baseline values (i.e., using ISHLT definition). Inherent to the
diagnosis of new BOS is the exclusion of other potential causes of allograft
dysfunction such as acute rejection, respiratory tract infection, and airway
anastomotic complications. Thus, sites are encouraged to conduct appropriate
evaluation for declining allograft function including bronchoscopy with
bronchoalveolar lavage (BAL) and lung biopsies if clinically appropriate to exclude
other potential causes of allograft dysfunction.

6. Achievement of a statistically significant rate of decline in lung function (FEV1) at
the diagnosis of new BOS per the criteria in Section 3.6 as assessed by the following

For patients who are monitored with laboratory based spirometry, at least five
recorded FEV1 measurements obtained at intervals of at least two weeks apart, over the
6 months preceding study enrollment accompanied by a statistically significant
(p<0.05) rate of decline of FEV1 that exceeds 30 mL/month; or For patients who are
monitored with home Spirometry (subject to Institutional Review Board (IRB) approval),
the Standardized Home Spirometry Method will define the specific criteria that will be
used for these patients.

7. Documented clinical assessment including a physical assessment and a CBC with WBC
within two weeks prior to enrollment.

EXCLUSION Criteria (Subjects meeting any one of these criteria will be excluded)

1. Current participation in another clinical treatment trial with an investigational

2. Any condition that may interfere with the subject's ability to perform pulmonary
function testing.

3. Known allergy or hypersensitivity to pharmacologic agents used during ECP

4. Any condition that would significantly affect the participant's ability to adhere to
the protocol, affect interpretation of the study results, or put the participant at
unacceptable risk for study-related complications as judged by the referring
clinician. This may include a) patients with a specific acute contraindication to
receiving ECP due to any acute condition such as new or evolving myocardial infarction
or central nervous system disorder, hemodynamic instability or hypovolemia, acute
bleeding, respiratory distress; or b) patients with lupus erythematosus, porphyria
cutanea tarda, erythropoietic protoporphyria, variegate porphyria, xeroderma
pigmentosum, albinism, or other dermatologic or ocular condition that contraindicates
the use of methoxsalen or markedly enhances photosensitivity in the investigator's

5. Aphakia or absence of ocular lenses

6. Pregnancy (positive pregnancy test - a urine or blood pregnancy test must be obtained
within 2 weeks prior to enrollment in women of childbearing potential)

7. Inability to provide informed consent or to comply with study treatments or
assessments (e.g. due to cognitive impairment or geographic distance)

8. Recent (i.e., within 2 weeks prior to enrollment) leukopenia (white blood cell count <
3,000 K/cumm)

9. Patients whose decline in lung function (FEV1) is related to either Restrictive
Chronic Lung Allograft Dysfunction (CLAD) or other causes that do not represent BOS
such as pneumonia, heart failure, etc.

For patients under review for eligibility for ECP for refractory BOS:

10. The most recent FEV1 < 900 mL

11. Rate of FEV1 decline within the last 6 months > 300 mL/month.

For patients under review for eligibility for RCT:

12. any patient who at least one year after transplant is treated with either lymphocyte
depleting therapy or with an escalated dose of steroids (i.e., prednisone greater than
30 mg/day) for more than one month for an acute decline in lung function that is
suspected to be secondary to acute cellular rejection.
We found this trial at
101 Jessup Hall
Iowa City, Iowa 52242
(319) 335-3500
Principal Investigator: Julia Klesney-Tait, MD
Phone: 319-467-5677
University of Iowa With just over 30,000 students, the University of Iowa is one of...
Iowa City, IA
Click here to add this to my saved trials
1720 2nd Ave S
Birmingham, Alabama 35233
(205) 934-4011 
Principal Investigator: Keith Wille, MD
Phone: 205-934-7433
University of Alabama at Birmingham The University of Alabama at Birmingham (UAB) traces its roots...
Birmingham, AL
Click here to add this to my saved trials
75 Francis street
Boston, Massachusetts 02115
(617) 732-5500
Principal Investigator: Hilary Goldberg, MD
Phone: 617-525-7638
Brigham and Women's Hosp Boston’s Brigham and Women’s Hospital (BWH) is an international leader in...
Boston, MA
Click here to add this to my saved trials
9500 Euclid Avenue
Cleveland, Ohio 44106
Principal Investigator: Marie Budev, DO
Phone: 216-444-2901
Cleveland Clinic Cleveland Clinic is committed to principles as presented in the United Nations Global...
Cleveland, OH
Click here to add this to my saved trials
Durham, North Carolina 27710
(919) 684-8111
Principal Investigator: John Reynolds, MD
Phone: 919-660-7224
Duke University Younger than most other prestigious U.S. research universities, Duke University consistently ranks among...
Durham, NC
Click here to add this to my saved trials
Gainesville, Florida 32610
(352) 392-3261
Principal Investigator: Andres Pelaez, MD
Phone: 352-273-7589
University of Florida The University of Florida (UF) is a major, public, comprehensive, land-grant, research...
Gainesville, FL
Click here to add this to my saved trials
116th St and Broadway
New York, New York 10027
(212) 854-1754
Principal Investigator: Selim Archasoy, MD
Phone: 646-317-5431
Columbia University In 1897, the university moved from Forty-ninth Street and Madison Avenue, where it...
New York, NY
Click here to add this to my saved trials
4200 Fifth Ave
Pittsburgh, Pennsylvania 15260
(412) 624-4141
Principal Investigator: Matthew Morrell, MD
Phone: 412-864-6371
University of Pittsburgh The University of Pittsburgh is a state-related research university, founded as the...
Pittsburgh, PA
Click here to add this to my saved trials
1500 E Medical Center Dr
Ann Arbor, Michigan 48109
(734) 936-4000
Principal Investigator: Kevin Chan, MD
Phone: 734-615-8627
University of Michigan Health System The University of Michigan is home to one of the...
Ann Arbor, MI
Click here to add this to my saved trials
303 East Superior Street
Chicago, Illinois 60611
Principal Investigator: Sangeeta Bhorade, MD
Phone: 312-695-2269
Chicago, IL
Click here to add this to my saved trials
281 W. Lane Ave
Columbus, Ohio 43210
(614) 292-6446
Principal Investigator: Brian Keller, MD
Phone: 614-292-0858
Ohio State University The Ohio State University’s main Columbus campus is one of America’s largest...
Columbus, OH
Click here to add this to my saved trials
Indianapolis, Indiana 46202
Principal Investigator: Chadi Hage, MD
Phone: 317-962-0485
Indianapolis, IN
Click here to add this to my saved trials
9500 Gilman Dr
La Jolla, California 92093
(858) 534-2230
Principal Investigator: Gordon Yung, MD
Phone: 858-657-5498
The University of California, San Diego UC San Diego is an academic powerhouse and economic...
La Jolla, CA
Click here to add this to my saved trials
Lexington, Kentucky
859) 257-9000
Principal Investigator: Maher Baz, MD
Phone: 859-323-1781
University of Kentucky The University of Kentucky is a public, land grant university dedicated to...
Lexington, KY
Click here to add this to my saved trials
2450 Riverside Ave
Minneapolis, Minnesota 55454
(612) 273-3000
Principal Investigator: Rade Tomic, MD
Phone: 651-747-4016
University of Minnesota Medical Center, Fairview Improving patients' lives drives the innovation that makes University...
Minneapolis, MN
Click here to add this to my saved trials
1801 N Broad St
Philadelphia, Pennsylvania 19122
(215) 204-7000
Principal Investigator: Francis Cordova, MD
Phone: 215-707-7281
Temple University Temple University is many things to many people. A place to pursue life's...
Philadelphia, PA
Click here to add this to my saved trials
350 W Thomas Rd
Phoenix, Arizona 85013
(602) 406-3000
Principal Investigator: Rajat Walia, MD
Phone: 602-406-3825
St. Joseph's Hospital and Medical Center St. Joseph's is a nationally recognized center for quality...
Phoenix, AZ
Click here to add this to my saved trials
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Principal Investigator: George Despotis, MD
Phone: 314-747-1931
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
Saint Louis, MO
Click here to add this to my saved trials